

AMENDMENTS TO THE CLAIMS

1. (Original) A spasmolytic comprising xenon or a xenon-containing gas mixture.
2. (Original) The spasmolytic as claimed in claim 1, characterized in that xenon is present in therapeutically effective amount.
3. (Currently amended) The spasmolytic as claimed in claim 1, in claim 1 or 2, characterized in that the spasmolytic comprises NO or an NO source in therapeutically effective amount.
4. (Currently amended) A spasmolytic as claimed in claim 1, comprising xenon or a xenon-containing gas and a spasmolytic which is administered orally or intravenously as combination product for simultaneous, separate or sequential use in the treatment of spasms.
5. (Original) The spasmolytic as claimed in claim 4, characterized in that the spasmolytic is used for the treatment of vasospasms.
6. (Original) A medicament comprising xenon and an NO source or comprising a xenon-containing gas and an NO source.
7. (Currently amended) The use of xenon or of a xenon-containing gas mixture according to claim 1, and, where appropriate, of an NO source to produce a medicament for the treatment of spasms, to produce a medicament for the treatment of vasospasms, to produce a medicament for the treatment of cerebral vasospasms, to produce a medicament for the treatment of impairments of blood flow, in particular to produce a gaseous medicament for the treatment of impairments of blood flow in the brain, to produce a medicament for the treatment of impairment of cerebral perfusion, to produce

a medicament for the treatment of coronary perfusion impairment, to produce a medicament for the treatment of cognitive impairments, to produce a medicament for the treatment of stroke, to produce a medicament for the prophylaxis of stroke, to produce a medicament for improving the oxygen supply in the brain, to produce a medicament for the treatment von post-ischemia syndrome or to produce a medicament for promoting blood flow in the brain, to produce a medicament for improving the oxygenation of the body, to produce a medicament for improving the oxygenation of the brain.

8. (Currently amended) The use of xenon or of a xenon-containing gas mixture according to claim 1, to produce a medicament having a vasodilating effect in capillary or precapillary vascular systems of the human body.

9. (Currently amended) The use of xenon or of a xenon-containing gas mixture according to claim 1, and, where appropriate, of an NO source to produce a medicament for the prophylaxis and/or therapy of impairments of cognitive performance, also postoperatively.

10. (Currently amended) The use of xenon or of a xenon-containing gas mixture according to claim 1, and, where appropriate, of an NO source for the treatment of spasms.

11. (Original) The use of xenon or of a xenon-containing gas, oxygen and, where appropriate, of an NO source for supplying oxygen to spontaneously breathing patients.